BETHESDA, Md., April 17 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq: SPEX) announced the recent hire of Randy Brown as Chief of Operations. Mr. Brown will be monitoring and overseeing all aspects of the ongoing Phase 3 clinical trial regarding the use of Naturlose(R) as a treatment for Type 2 diabetes. The hiring of Mr. Brown has allowed Spherix to terminate its agreement with the Contract Research Organization (CRO), take over full control of the clinical trial and its pivotal contracts, and build from existing internal resources, rather than outsource to third parties. Mr. Brown has spent 16 years in the pharmaceutical industry, most recently running the operations group for a CRO.
Mr. Brown said, "I am very pleased and excited to join the Spherix staff. Leading the efforts in our clinical program is a wonderful opportunity and I am looking forward to meeting the challenge. Our ability to pull the trials in-house will give us direct control of the program and potentially save us significant dollars. Simply put, it makes good business sense."
Spherix further announced the recent hire of an experienced toxicologist to assist with the many ongoing Health Sciences Consulting projects. This business segment provides technical and regulatory consulting services to several major consumer, food, ingredient, and pharmaceutical companies, and is continuing to grow.
Certain statements contained herein are "forward looking" statements as
defined in the Private Securities Litigation Reform Act of 1995. Because
such statements include risks and uncertainties, actual results may differ
materially from those expressed or implied. Factors that could cause actual
results to differ materially from those expressed or implied
|SOURCE Spherix Incorporated|
Copyright©2008 PR Newswire.
All rights reserved